Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.


25 November 2020

Successful virtual General Assembly Meeting

On 24-25 Nov 2020, 51 members of the DECISION consortium and 4 members of the Scientific and Ethical Advisory Board met online to discuss the progress made during the first 8 months and important next steps. Despite the COVID-19 pandemic, the project is largely on track and important first results have been delivered. Still we all cannot wait to meet in person next time to speed up the communication and international collaboration!

More news


29 August 2020

1st Digital International Liver Congress (Digital ILC)

The 1st Digital International Liver Congress (Digital ILC, #ILC2020) took place from 27-29 August 2020. DECISION was represented with a virtual booth and several talks given by members.

Read More
More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more